Xceleron News and Events

12/3/09 Development and Validation of HPLC-AMS Method for Quantification of [14C]-CC-11050 in Human Plasma

Fri, 04 Dec 2009 00:00:00 GMT

Poster presented at AAPS Annual Conference, LA, California, November 2009 by Celgene Corporation, NJ. Validation of HPLC-AMS Method for Quantification of [14C]-CC-11050 in Human Plasma.

11/20/09 Intravenous and Oral Microdose Pharmacokinetics of Three Novel Inhibitors of FabI in Healthy Subjects

Mon, 23 Nov 2009 00:00:00 GMT

Poster presented at AAPS Annual Conference, LA, California, November 2009. With Affinium Pharmaceuticals and Quotient Clinical. Intravenous and Oral Microdose Pharmacokinetics of Three Novel Inhibitors of FabI in Healthy Subjects

10/14/09 Microdose Pharmacokinetics of two NNRTI's published. Idenix's lead compound in-licensed by GSK.

Wed, 14 Oct 2009 00:00:00 GMT

Microdose data of two Candidate HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

8/18/09 Xceleron Expands Agreement with GSK

Tue, 18 Aug 2009 00:00:00 GMT

August 18, 2009 â XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline.

8/10/09 Value of Phase Zero - Next Generation Pharmaceuticals

Mon, 10 Aug 2009 00:00:00 GMT

Michael Butler looks at the value a microdose study adds to a drug
development program.

7/24/09 AMS and PET in Microdose studies - International Clinical Trials August 2009

Fri, 24 Jul 2009 00:00:00 GMT

Studying drug disposition and pharmacokinetics with PET and AMS offers numerous benefits; Graham Lappin and Marie Simpson of Xceleron and Oliver Langer of the Department of Clinical Pharmacology, the Medical University of Vienna, report their findings.

7/13/09 Outcomes from EUMAPP - A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics

Mon, 13 Jul 2009 00:00:00 GMT

The European Microdosing AMS Partnership Programme (EUMAPP), funded by the European Union, was a major international, multi-centre research study involving collaboration between industry and academia.
The objectives of EUMAPP were:
â¢ To assess if there was pharmacokinetic linearity following a microdose and a therapeutic dose for 7 drugs representative of situations where traditional pharmacokinetic predictive models (eg in vitro and animal species) are problematic.
â¢ To compare the accuracy of the pharmacokinetic predictions made by microdosing to those made from physiologically based pharmacokinetic (PB-PK) computer models.

Follow Xceleron on Twitter!

Mon, 04 May 2009 00:00:00 GMT

Click on the link below to follow Xceleron on Twitter.

4/28/09 Xceleron Launches Solution to FDA MIST

Tue, 28 Apr 2009 00:00:00 GMT

April 28, 2009 GERMANTOWN, MD â XCELERON, a global leader of translational science in clinical research, today announced the launch of its fast and cost-effective solution to the FDA âSafety Testing of Drug Metabolitesâ guidance (also known as MIST: âMetabolites in Safety Testingâ).

3/25/09 Five compound Phase 0 Human Microdose useful in candidate selection

Wed, 25 Mar 2009 00:00:00 GMT

February 2009: A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects

Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma

Tue, 10 Feb 2009 00:00:00 GMT

LONDON - 10 February, 2009 - Microdosing or Phase 0 clinical testing has been gaining acceptance and might become an imperative phase of the drug development process in the years to come. The emergence of niche capability providers in preclinical testing and technology dependence is also expected to result in numerous partnerships and alliances, fuelling growth opportunities in this sector.

Xceleron Names Michael Butler as President & CEO

Tue, 16 Dec 2008 00:00:00 GMT

December 16, 2008: Butler Brings Strong Leadership, Vision and Experience to Xceleron

Human Drug Metabolism Earlier - International Clinical Trials Autumn 2008

Thu, 27 Nov 2008 00:00:00 GMT

Earlier Metabolism Information derisks later stages of development

Xceleron and Otsuka sign META-ID deal

Mon, 17 Nov 2008 00:00:00 GMT

November, 17 2008; Xceleron to Provide Otsuka Pharmaceutical Development & Commercialization, Inc. with META-IDâ¢ Services
to Obtain Critical Metabolism Information at Phase I.

Using Microdosing to Enhance Development of anti-infectives- Gen Eng News Nov 2008

Wed, 05 Nov 2008 00:00:00 GMT

Early Availability of PK Information Allows for Selection of Potentially Promising Molecules

Human Microdosing Greater Than 80% Predictive in 25 Tested Molecules

Thu, 29 May 2008 00:00:00 GMT

Latest Human Microdose data from 7 new compounds will be presented as part of the June 16, 2008 European Federation of Pharmaceutical Sciences (EUFEPS) Conference in Bad Homburg, Germany.

8 December, 2009: Advances in Analytical Technologies for DMPK : Sample Preparation, Automation, Mass Spectrometry and Imaging

Fri, 28 Aug 2009 00:00:00 GMT

Come and meet Xceleron at this California Analytical Chemists Organization (CACO) workshop. Please stop by at our booth

8 September, 2009: Clinical Pharmacokinetics & Pharmacodynamics in Drug Development

Fri, 28 Aug 2009 00:00:00 GMT

Come meet with Xceleron at the California Analytical Chemists Organization (CACO) workshop. Please stop by at our booth

30 September, 2009: Drug Metabolite Identification

Fri, 28 Aug 2009 00:00:00 GMT

Come and meet with Xceleron at this California Analytical Chemists Orgnization (CACO) workshop. Please stop by at our booth

14-16 Oct 2009: Dr. Mark Seymour presents at GTC BIO's 5th Modern Drug Discovery and Development Summit (M3D)

Mon, 17 Aug 2009 00:00:00 GMT

GTC BIO 5th Modern Drug Discovery and Development Summit (M3D) October 14-16, 2009. San Diego, CA

31 May - 4 June 2009: 57th ASMS Conference on Mass Spectrometry

Thu, 21 May 2009 00:00:00 GMT

Monday PM session will cover the use of AMS for Human Microdosing (Phase 0) and Metabolism Studies.

14-18 June, 2009: 10th International Symposium of the International Isotope Society

Thu, 21 May 2009 00:00:00 GMT

Dr. Graham Lappin will be participating in a round table discussion on the use of AMS

13-14 May, 2009: Exploratory Clinical Development - London

Mon, 27 Apr 2009 00:00:00 GMT

Jeremy Hague, will be attending this years Exploratory Clinical Development Congress in London.

May 18-21, 2009: BIO International Conference

Mon, 23 Mar 2009 00:00:00 GMT

Xceleron will be at BIO International partnering to discuss how early ADME and PK data can improve decision making in early drug development.